Skip to main content

Table 1 The baseline characteristics in this study

From: Association of circulating proprotein convertase subtilisin/kexin type 9 concentration, prothrombin time and cardiovascular outcomes: a prospective cohort study

 

Overall

MACEs

non-MACEs

n = 2293

n = 186

n = 2107

p

Clinical data

 Age (years)

55.62 ± 11.01

57.73 ± 9.8

55.44 ± 11.09

0.006

 Male sex n(%)

1387 (60.5)

111 (59.7)

1276 (60.6)

0.813

 BMI (kg/m2)

25.63 ± 3.38

25.95 ± 3.37

25.6 ± 3.38

0.175

 CAD n(%)

1447 (63.1)

142 (76.3)

1305 (61.9)

< 0.001

 DM n(%)

538 (23.5)

60 (32.3)

478 (22.7)

0.003

 Hypertension n(%)

1418 (61.8)

125 (67.2)

1293 (61.4)

0.116

 Smoking n(%)

788 (34.4)

63 (33.9)

725 (34.4)

0.882

 Drinking n(%)

468 (20.4)

44 (23.7)

424 (20.1)

0.252

 Family history of CAD n(%)

514 (22.4)

30 (16.1)

484 (23)

0.032

 SBP (mmHg)

128.05 ± 18.01

129.57 ± 16.49

127.92 ± 18.13

0.231

 DBP (mmHg)

79.59 ± 11.19

80.25 ± 11.98

79.53 ± 11.12

0.398

Laboratory parameters

 TC (mmol/L)

4.9 ± 1.09

5.09 ± 1.08

4.88 ± 1.09

0.014

 TG (mmol/L)

(1.15,2.3)

1.65 (1.17,2.36)

1.58 (1.14,2.29)

0.598

 HDL-C (mmol/L)

1.11 ± 0.35

1.11 ± 0.34

1.16 ± 0.37

0.074

 LDL-C (mmol/L)

3.2 ± 1.0

3.35 ± 1.01

3.18 ± 1.0

0.030

 Glu (mmol/L)

5.65 ± 1.88

5.84 ± 2.44

5.63 ± 1.83

0.145

 HbA1C (%)

6.02 ± 1.0

6.24 ± 1.06

6.0 ± 1.0

0.001

 hsCRP (mg/L)

1.37 (0.72,2.46)

1.65 (0.77,2.89)

1.36 (0.72,2.46)

0.192

 PCSK9 (ng/mL)

228.48 (189,275.5)

246.69 (208.92,297.11)

227.24 (187.33,274.18)

< 0.001

Coagulation indexes

 APTT (s)

36.25 ± 3.9

36 ± 3.91

36.27 ± 3.89

0.374

 PT (s)

12.75 ± 0.64

12.66 ± 0.58

12.76 ± 0.64

0.032

 PT-t (1/s)

0.83 (0.63.1.25)

0.91 (0.70,1.25)

0.83 (0.63,1.25)

0.028

 TT (s)

16.4 ± 1.25

16.28 ± 1.55

16.41 ± 1.22

0.170

 Fib (g/L)

3.06 ± 0.73

3.19 ± 0.85

3.05 ± 0.71

0.013

 D dimer (μg/mL)

0.31 (0.24,0.41)

0.31 (0.23,0.45)

0.31 (0.24,0.41)

0.531

 Platelet(10^12)

216.79 ± 55.66

212.69 ± 49.81

217.15 ± 56.14

0.295

Medication

 Aspirin/Clopidogrel n(%)

748 (32.6)

72 (38.7)

676 (32.1)

0.065

 ACEI/ARB n(%)

383 (16.7)

34 (18.3)

349 (16.6)

0.548

  1. BMI body mass index, CAD coronary artery disease, DM diabetes mellitus, SBP systolic blood pressure, DBP diastolic blood pressure, TC total cholesterol, TG triglyceride; HDL-C, high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, Glu glucose, HbA1C hemoglobin A1C, hs-CRP high-sensitivity C-reactive protein, PCSK9 proprotein convertase subtilisin/kexin type 9, APTT activated partial thromboplastin time, PT prothrombin time, PT-t transformation of prothrombin time (the inverse of the difference between PT and the minimal PT of normal plasma), TT thrombin time, Fib fibrinogen, ACEI angiotensin converting enzyme inhibitors, ARB angiotensin receptor blockers. p < 0.05 suggested significant difference